Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1

Bernadien M. Nijmeijer and Teunis B. H. Geijtenbeek*

Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, Netherlands

Sexual transmission of HIV-1 consists of processes that exert either positive or negative selection pressure on the virus. The sum of these selection pressures lead to the transmission of only one specific HIV-1 strain, termed the transmitted founder virus. Different dendritic cell subsets are abundantly present at mucosal sites and, interestingly, these DC subsets exert opposite pressure on viral selection during sexual transmission. In this review we describe receptors and cellular compartments in DCs that are involved in HIV-1 communication leading to either viral restriction by the host or further dissemination to establish a long-lived reservoir. We discuss the current understanding of host antiretroviral restriction factors against HIV-1 and specifically against the HIV-1 transmitted founder virus. We will also discuss potential clinical implications for exploiting these intrinsic restriction factors in developing novel therapeutic targets. A better understanding of these processes might help in developing strategies against HIV-1 infections by targeting dendritic cells.

Keywords: dendritic cell, langerhans cell, transmitted founder HIV-1, IFITM, Type I IFN, Trim5a, viral restriction and dissemination

INTRODUCTION

The number of new HIV-1 infections globally continues to decline. From a peak of 3.4 million new infection a year in 1996 to 1.8 million in 2017. The intervention of early combination antiretroviral therapy (cART) is clinically beneficial to patients and very effective in preventing HIV-1 transmission (1–3). The introduction of pre-exposure prophylaxis (PrEP) will further interfere with HIV-1 transmission (4–6). However, currently there is no curative treatment or vaccine to prevent HIV-1 infection. Uncovering the mechanism underlying viral transmission and pathogenesis is crucial to develop methods to prevent HIV-1 transmission. Sexual transmission of HIV-1 results most commonly from virus exposure at mucosal surfaces (7, 8). The identification of transmitted founder (TF) viruses emphasizes the existence of selection pressure mechanisms that lead to the transmission of only specific HIV-1 strains (9). Host factors influence whether virus exposure leads to productive infection. These may include the physical barrier of the mucosa (10), the amount of available target cells (11), altered mucosal microbiota (12, 13), and immune activation by genital inflammation established by other sexual transmitted infection...
Also, genital fluids are known to contain proteins that enhance viral infection, like semen-derived enhancer of virus infectivity (SEVI) and complement (Figure 1) (19, 20). The transmission risk is associated with the specific within-host barriers, which creates a selection bias with an advantage for viruses with higher between-host transmission potential (21–24). Important cells that exert opposing selection pressures are the different dendritic cell (DC) subsets localized in the mucosal tissues.

**VIRUS-HOST INTERACTIONS AT MUCOSAL SITES**

DC subsets play an important role in transmission of viruses such as HIV-1 across mucosal tissues (14, 25). The cellular plasma membrane is the first interaction of HIV-1 with its host and an important step in viral transmission and pathogenesis. HIV-1 spreads either as cell-free virus particles or via cell-cell transmission. While cell-free virus allows spread of virions in more distant tissues, cell-cell transmission is much more efficient and it helps the virus to overcome physical and immunological barriers (26). In vitro studies illustrate that cART and broadly neutralizing antibodies (bNAb) do not neutralize HIV-1 cell-cell transmission as potent as cell-free spread (27–29), which underscores the importance of understanding the mode of viral transmission for drug design.

The compartments where fusion of HIV-1 with the host cell occurs differs and is dependent on the cell type and mode of viral transmission. For CD4 T cells, HIV-1 fuses at the plasma membrane using the CD4 receptor and a co-receptor such as CCR5 and CXCR4 (30–32). For DCs viral fusion occurs at the plasma membrane (33) or after internalization via clathrin mediated endocytosis (34, 35). Internalization minimizes the exposure of viral epitopes at the cell surface, thereby reducing the efficacy of inhibitors targeting these epitopes (35). In contrast, endocytosis does not always lead to productive infection. When HIV-1 is endocytosed in multivesicular bodies (MVBs) the virus can be recycled back toward the plasma membrane for transfer to uninfected cells (36, 37). However, internalization can also lead to autophagic destruction in specific cells (38). Indeed, different DC subsets have distinct roles in HIV-1 dissemination because of the differences in handling the virus. Mucosal langerhans cells (LCs) capture and internalize HIV-1 leading to degradation, thereby preventing HIV-1 dissemination (38, 39), whereas DCs play a key role in transmitting the virus to target CD4 T cells.

**DENDRITIC CELLS FACILITATE HIV-1 DISSEMINATION UPON SEXUAL CONTACT**

DCs patrol the submucosal tissues to capture invading pathogens for antigen presentation to T cells in the lymph nodes, thereby facilitating HIV-1 transmission (Figure 1) (40). DCs facilitate viral transmission to T cells either by HIV-1 fusion and productive infection of the DC, leading to viral transmission to permissive cells or by capture and internalization of HIV-1 into MVBs and transmission independent of DC infection (36, 37, 41). Besides their role in HIV-1 dissemination they are also important in triggering an innate immune response upon viral exposure. DCs express relatively low levels of the CCR5 and CXCR4 co-receptor and CD4 entry receptor, which could account for the lower levels of infection seen in DCs (42). DCs express many attachment molecules that mediate virus internalization and transfer. Indeed, the C-type lectin receptor (CLR) DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is thought to play an important role in HIV-1 binding and internalization via endocytosis into clathrin coated pits (41, 43, 44). After internalization the virions can stay infectious for many days and can be transmitted to CD4-positive T cells (45). In this way DCs serve as virus reservoirs to mediate trans-infection of CD4-positive T cells, thereby facilitating spread of HIV-1 to the lymph nodes (45, 46). DC-SIGN is highly expressed on in vitro-generated monocyte-derived DCs (moDCs), at mucosal sites on CD14-positive dermal DCs (dDCs) and on sub epithelial-based vaginal myeloid DCs (47–49). For DCs that do not express DC-SIGN (50), different attachment receptors like Siglec-1 (CD169) have been identified to transfer HIV-1 (51, 52). Also external factors can promote trans-infection, like semen fluid, which contains fragments of prostatic acid phosphatase forming amyloid aggregates termed SEVI that promote viral attachment to DCs thereby increasing trans-infection of CD4-positive T cells by HIV-1 (19, 53). There are different processes described by which trans-infection occurs. One process is internalization via clathrin-mediated endocytosis (41, 43, 44). Antigen bound to DC-SIGN in mature DCs localizes in compartments with a neutral pH close to the cell surface, which could represent early endosomes (43). In contrast, in immature DCs DC-SIGN co-localizes with late endosomes or lysosomes (41). A different trans-infection route is dependent on invagination. For mature DCs, HIV-1 is internalized in a CD81 tetraspanin rich compartment, which is distinct from endocytic vesicles but adjacent to the plasma membrane (36, 54). This allows protected transfer of virions by DCs and delivery to target cells in the lymph node. Interestingly, more recently it has been shown that a process called micropinocytosis is involved in transfer of HIV-1 from immature DCs to CD4-positive T cells. Dynamin 2 (DNM2), a gene involved in organelle and membrane trafficking limits HIV-1 endocytosis and maintains virions on the surface of DCs for efficient transfer (55). Once in the lymph node HIV-1 can be transmitted from DCs to T cells via different mechanisms. DC-SIGN-bound HIV-1 facilitates optimal contact with CD4 and CXCR4/CCR5 co-receptors on T cells, enhancing viral transfer (56), HIV-1 is transferred via virological synapses which is formed by direct contact between DCs and T cells (57–59) or DCs transfer HIV-1 to T cells via exosomes (60, 61). Interestingly, exosomes derived from HIV-1 infected cells contain HIV-1 viral genome (62) and are able to establish productive infection in target cells (61, 63). All these mechanisms contribute to viral escape and promote further dissemination in the newly infected host.
LANGERHANS CELLS ARE EITHER PROTECTIVE AGAINST OR PROMOTE HIV-1 TRANSMISSION

LCs are a subset of DCs that are abundantly present at epithelia of vagina, foreskin, and within the anal tissues and under normal conditions are therefore the first immune cells to encounter HIV-1 during sexual transmission. Langerin (CD207) is a CLR expressed almost exclusively by LCs and is important for antigen capture and internalization, which induces Birbeck granules formation and routing of antigen into organelles. In contrast to DC-SIGN, langerin has a role in antiviral protection as immature LCs do not become infected by HIV-1 but capture HIV-1 via langerin, leading to TRIM5α-mediated degradation of HIV-1 and thereby preventing HIV-1 dissemination. This implies that activation of LCs by inflammation or genital coinfection alters the protective function of LCs, mediating HIV-1 transmission, which might be associated with lower expression of langerin on activated LCs as langerin has anti-viral properties.

INTERFERON PRESSURE AT MUCOSAL SITES

Viral infections sensed by pattern recognition receptors (PRRs) lead to the activation of signaling cascades that results in the release of interferons (IFNs). Upregulation of type I IFN production is one of the earliest innate responses observed in HIV-1 infection. Production of type I IFNs during viral infections promotes an antiviral environment by an autocrine feedback loop triggering the IFN receptor and subsequently inducing cellular expression of IFN-stimulated genes (ISGs) within the infected cells but also in bystander cells. Several studies have shown that HIV-1 is able to escape intrinsic IFN-β response triggering by limiting replication of viral DNA or actively...
blocking virus sensing by PRRs, which contributes to efficient HIV-1 replication (72). Besides cellular IFN responses upon viral infection, plasmacytoid dendritic cells (pDCs) secrete a second wave of type I IFNs in response to viruses or tissue damage (73, 74). pDCs develop in the bone marrow and circulate in the blood. Macaque studies have shown that upon SIV exposure, pDCs are recruited to the mucosal sites of virus transmission, become activated and start producing high levels of type I IFNs (75). The outcome of this high IFN response by pDCs has conflicting functions in antiviral defense. Some of the induced ISGs act as host restriction factors to prevent HIV-1 infection and dissemination. In contrast, during acute infections, IFN produced by pDCs results in maturation of bystander myeloid DCs that play a crucial role in transporting the virus to secondary lymphoid organs thereby promote transmission (Figure 1) (74). It has been shown that DCs upregulate the interferon-inducible receptor Siglec-1 which is able to transfer HIV-1 to T cells (76). Also, studies show that ISGs are upregulated during chronic infection (77, 78). The persistent activation of pDCs during chronic infection may contribute to immune activation and inflammation, which is associated with AIDS disease progression (79, 80). These consequences of high IFN production promote viral dissemination. Earlier studies suggested that IFN-α responses in mucosa of non-human primates could enhance infection and the IFN-α induction did not protect animals from SIV infection (75, 81). However, IFN production may also create an antiviral environment. Recently an elegant study showed that early type I IFN responses in macaques prevent SIV infection and slow disease progression (82). Moreover, in uninfected but high exposed individuals, higher IFN-α levels have shown to be protective against infection (83). Also, the induction of an effective early antiviral immune response at mucosal sites creates selective pressure for viruses that are resistant to type I IFN (84).

HOST ANTIRETROVIRAL RESTRICTION FACTORS AGAINST HIV-1

Host restriction factors play an important role in suppressing retroviral replication and dissemination (Figure 1). Many restriction factors that target HIV-1 are induced by type I IFN. Well-known HIV-1 restriction factors in DCs are IFITM (Interferon-induced transmembrane proteins), TRIM5α (E3-ubiquitin ligase tripartite-containing motif 5a) (38), SAMHD1 (SAM- and HD domain-containing protein 1) (95), APOBEC3 (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3) (96), Mx2 (Myxovirus resistance 2), and bone marrow stromal antigen 2 (BST2 or Tetherin) (97). Because of the potent antiviral potential of IFN many viruses have developed mechanisms to promote their survival. HIV-1 although sensitive to type I IFNs, is able to antagonize host restriction factors that inhibit virus entry to facilitate viral dissemination (Figure 1) (98). HIV-1 accessory proteins well known to counteract important restriction factors are: viral protein R (Vpr) viral infectivity factor (Vif) which antagonizes APOBEC3 proteins, negative regulatory factor (Nef) and viral protein unique (Vpu) antagonizing BST2 (99, 100).

IFITMs are small membrane-associated cellular factors that inhibit the replication of HIV-1 at the entry step (101). IFITMs do not block the internalization of viruses but inhibit fusion of the virus with the host cell. Whether HIV-1 is sensitive to IFITM restriction is determined by the subcellular localization of the IFITMs and HIV-1 co-receptor usage (102). TF viruses are more resistant to the antiviral activity of IFITMs. The ability by TF viruses to evade IFITM restriction is due to its relative resistance to IFN. Interestingly, IFITM restriction contributes to the increased IFN sensitivity of chronic HIV-1 viruses (102).

TRIM5α targets incoming retroviral capsid before integration to block infection. TRIM5α expression levels and polymorphisms have been associated with the clinical course of HIV-1 infection.
in cohort studies underscoring the antiviral effect of TRIM5α (103–105). Unique about TRIM5α is that it can restrict diverse retroviruses in a species-specific manner. Rhesus TRIM5α (rhTRIM5α) strongly restricts HIV-1, whereas human TRIM5α has been thought to have poor restriction activity against HIV-1 (106). More recently some primary isolates of HIV-1 have been found to be more sensitive to human TRIM5α restriction than lab strains (107, 108). So restriction of TRIM5α on replication may vary according to the virus. The functional capacity of TRIM5α also depends on the localization of the restriction factor in the cell. It has been suggested that non-human primate DCs lack efficient TRIM5α mediated retroviral restriction because TRIM5α is unable to restrict incoming viruses because it is absent from the cytoplasm (109). TRIM5α localization to the nucleus triggers induction of type I IFN during infection (109). Notably, recent data show that TRIM5α restriction might be cell specific. Immature LCs protect against HIV-1 infection by inducing langerin-mediated autophagic degradation of captured HIV-1 (38). The LC specific restriction factor TRIM5α is dependent on the CLR function. HIV-1 binding to Langerin routes HIV-1 into the TRIM5α mediated restriction pathway which targets virions for degradation and thereby prevents infection of LCs. Taken together, the outcome of these studies support a role for human TRIM5α in HIV-1 transmission and pathogenesis in vivo.

SAMHD1 is highly expressed in myeloid cells like DCs and macrophages (95). SAMHD1 also targets the early phase of viral infection as it inhibits reverse transcription by depleting the pool of cellular dNTPs (95, 110, 111). HIV-2 viral protein X (Vpx) is able to counteract SAMHD1 restriction. Degrading SAMHD1 by treating DCs with SIV-Vpx leads to infection and maturation of DCs promoting viral dissemination (95). Whether HIV-1 infection leads to DC maturation is unclear as it has been shown that interfering with SAMHD1 restriction increases infection of DCs but not DC maturation (112). Furthermore, higher infection observed with SAMHD1 depletion correlates with a stronger suppression of maturation, suggesting that HIV-1 might actively suppress PRR sensing (112). HIV-1 complement opsonization bypasses SAMHD1 restriction in DCs by enhancing SAMHD1 phosphorylation, which results in DC infection (113).

Upon HIV-1 infection APOBEC3 is encapsulated into budding virions. In newly infected cells during reverse transcription of the viral RNA, APOBEC3G triggers G-to-A hypermutations leading to the production of defective proteins and non-functional virus particles which results in a strong inhibition of HIV-1 replication (96). Interestingly, exosomes can transfer host restriction factors such as APOBEC3 from cell to cell and thereby inhibit HIV-1 infection (114). Vif antagonizes APOBEC3 proteins by inducing the recruitment of proteins leading to polyubiquitylation and proteosomal degradation of APOBEC3, thereby preventing incorporation of APOBEC3 into virions (115, 116).

BST2 or Tetherin prevents the release mature Env virions by anchoring virions to the plasma membrane of infected cells (117, 118). The retention of viral particles at the plasma membrane leads to endocytic uptake and the accumulation of these virions in endosomes which may result in viral degradation and thereby inhibit the spread of newly formed virions (119). Similarly, Vpu interacts with tetherin, preventing tetherin trafficking to the cell surface, promoting ubiquitination and subsequent targeting to late endosomes and degradation in lysosomes (118, 120). This prevents incorporation of tetherin into virions thereby enhancing viral budding and release.

Accessory proteins positively contribute to transmission by allowing HIV-1 to escape host restriction. The continuous adaptation of HIV-1 to the antiviral activity of host restriction factors emphasizes their importance in controlling HIV-1 infection and viral transmission.

UNDERSTANDING HOST-VIRUS INTERACTIONS FOR SPECIFIC INTERVENTIONS

Mucosal DCs are among the first immune cells to encounter HIV-1 upon sexual contact. Therefore, receptors expressed or host antiviral factors induced by DCs or LCs could be used in immunotherapeutic strategies to prevent HIV-1 transmission. Langerin binds to glycan ligands for pathogen capture and internalization. A recent study identified chemical compounds with a high binding affinity to langerin (121). Interestingly, these compounds were found to modulate cellular signaling and to suppress inflammation (121, 122). Also, it has been shown that rhTRIM5α is very potent in HIV-1 restriction. Interestingly, human TRIM5α restriction is specific for LCs and is dependent on HIV-1 binding to langerin. Therefore, targeting langerin, host restriction factors like TRIM5α and other ISGs that contribute significantly to viral control could be interesting candidates for therapeutic applications (125). A better understanding of the specific properties of TF viruses, which will relate to different selection biases during transmission, will allow us to identify the specific selection mechanisms and thereby providing novel strategies to counteract the transmission of these TFs (24). The majority of TF viruses are of R5 tropisms and use CCR5 co-receptor for their initial infection, which makes CCR5 an interesting candidate for blocking early transmission. The higher incorporation of Env per particle may increase the sensitivity to neutralization by antibodies.

CONCLUDING REMARKS

At mucosal sites DC subsets patrol the microenvironment and are therefore the first cells to interact with HIV-1 after exposure. If the virus carries specific properties and interacts with DCs or LCs determines the fate of the virus which can result in either routing of the virus for degradation or further dissemination. Strategies to counteract suppression mechanisms by HIV-1 leading to HIV-1 sensing and induction of type I IFN responses upon viral infection can be a powerful strategy to restrict viral dissemination. The induction
of host factors and the ability of HIV-1 to counteract viral restriction shows the intricate interplay between HIV-1 and host. Further understanding of the specific within-host barriers provides new insights important for developing novel therapeutic approaches at the site of initial infection. Understanding the specific properties of TF viruses that create advantages to promote between-host transmission may contribute to the development of immunotherapeutic strategies to combat HIV-1 dissemination.

REFERENCES

1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. (2016) 375:830–9. doi: 10.1056/NEJMoA1606993

2. Group the insight start study. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. (2015) 373:795–807. doi: 10.1056/NEJMoA1506816

3. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppression antiretroviral therapy (PARTNER): final results of a multicentre, observational study. Lancet. (2019) 393:2428–38. doi: 10.1016/S0140-6736(19)30418-0

4. Mccormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): eff cettiness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. (2016) 387:53–60. doi: 10.1016/S0140-6736(15)00556-2

5. Grant RM, Lama JR, Anderson PL, McMahan V, Lui AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. (2010) 2010:2587–99. doi: 10.1056/NEJMa1012105

6. Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, et al. The impact of HIV-1 within-host evolution on transmission dynamics. Defic Syndr. (2017) 76:43–7. doi: 10.1097/QAI.0000000000001458

7. Robin S, Moore JP. Inhibiting sexual transmission of HIV-1 infection. J Clin Invest. (2008) 113:2524–33. doi: 10.1172/JCI34721

AUTHOR CONTRIBUTIONS

BN: designed and wrote the manuscript. TG: designed and edited the manuscript.

FUNDING

This work was supported by Aidsfonds (P-11118) and European Research Council, Advanced grant (670424).
7. Feng, Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. (1996) 272:782–7. doi: 10.1126/science.272.5263.872

8. Chauveau L, Donahue DA, Schwartz O, Mend B, Brout T, Casartelli N, et al. HIV fusion in dendritic cells occurs mainly at the surface and is limited by low CD4 levels. J Virol. (2017) 91:e01248-17. doi: 10.1128/JVI.01248-17

9. Li Q, Li W, Yin W, Guo J, Zhang Z, Zeng D, et al. Single-particle tracking of human immunodeficiency virus type 1 productive entry into human primary macrophages. ACS Nano. (2011) 11:3890–903. doi: 10.1021/acs.nano.0b00275

10. Miyatachi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell. (2009) 137:433–44. doi: 10.1016/j.cell.2009.02.046

11. Yu HJ, Reuter MA, McDonald D. HIV trafficking through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog. (2008) 4:e1000134. doi: 10.1371/journal.ppat.1000134

12. Garcia E, Pion M, Pelchen-Matthews A, Collinson L, Arrighi JF, Blot G, et al. HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. Traffic. (2005) 6:488–501. doi: 10.11101.1600-0854.2005.00293.x

13. Ribeiro CMS, Sarrami-Forooshani R, Setiawan LC, Zijlstra-Willems EM, Van Hamme JL, Tighelt-az W, et al. Receptor usage dictates HIV-1 infection by human TRIM5α by human TRIM5α. J Virol. (2016) 90:448–52. doi: 10.1128/jvi.020567

14. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong M a WP, de Gruyl T, et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med. (2007) 13:367–71. doi: 10.1038/nm1541

15. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. (1998) 392:245–52. doi: 10.1038/32588

16. Engering A, Geijtenbeek TBH, van Vliet SJ, Wijers M, van Liempt E, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Proc Natl Acad Sci USA. (2010) 107:13336–41. doi: 10.1073/pnas.1003040107

17. Borras FE, Connor JH, Gummuluru S, Archer J, Hatch SC, Clotet B, et al. Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-diseminisation pathway. Blood. (2008) 113:2732–41. doi: 10.1182/blood-2008-05-158662

18. Wiley RD, Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV-1 infection. Proc Natl Acad Sci USA. (2006) 103:738–43. doi: 10.1073/pnas.0507995103

19. Chahar HS, Bao X, Cosala A. Exosomes and their role in the life cycle and pathogenesis of RNA viruses. Viruses. (2015) 7:3204–25. doi: 10.3390/v7062770

20. Kulkarni R, Prasad A. Exosomes derived from HIV-1 infected DCs mediate viral trans-infection via fibronectin and galectin-3. J Invest Dermatol. (2019) 22:e25268. doi: 10.1002/jia2.25268

21. Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, et al. Langerin, a novel C-type lectin specific to langerhans cells, is an endocytic receptor that induces the formation of birbeck granules. Immunity. (2000) 12:71–81. doi: 10.1016/S1074-7613(00)80160-0

22. Yaron Y, Zhou Z, Tudor D, Wolf J-P, Thiounn N, Tomasini J, et al. Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans–T cell conjugates. Mucosal Immunol. (2010) 3:506–22. doi: 10.1038/mi.2010.32

23. Nijmeijer B, Sarrami-Forooshani R, Steba G, Schreurs R, Koekkkoek S, Molenkamp R, et al. HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells. J Int AIDS Soc. (2019) 22:e25268. doi: 10.1002/jia2.25268

24. Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, et al. Langerin, a novel C-type lectin specific to langerhans cells, is an endocytic receptor that induces the formation of birbeck granules. Immunity. (2000) 12:71–81. doi: 10.1016/S1074-7613(00)80160-0

25. Ballweber L, Robinson B, Kreger A, Fialkow M, Lentz G, McKlrlath MJ, et al. Vaginal langerhans cells nonproductively transporting HIV-1 mediates transfer of HIV infection. J Virol. (2011) 85:13443–7. doi: 10.1128/JVI.05615-11

26. Nasr N, Lai J, Botting RA, Mercier SK, Harman AN, Kim M, et al. Inhibition of two temporal phases of HIV-1 transfer from primary langerhans cells to T cells: the role of langerin. J Immunol. (2014) 193:2554–64. doi: 10.4049/jimmunol.1400633

27. Introuli A, Vanpouille C, Liso A, Grivel JC, Margolis L. Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. PLoS Pathog. (2013) 9:e1003148. doi: 10.1371/journal.ppat.1003148
Nijmeijer and Geijtenbeek

Selection Pressure During HIV-1 Transmission

870. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferon. Annu Rev Biochem. (1998) 67:227–64. doi: 10.1146/annurev.biochem.67.1.227

871. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Litman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature. (2010) 467:214–7. doi: 10.1038/nature09337

872. Gringhuis SI, Hertoghs N, Kaptejn TM, Zijlstra-Willems EM, Sarrami-Forooshani R, Sprokhold JK, et al. HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after sensing of abortive HIV-1 RNA by the host helicase DDX3. Nat Immunol. (2017) 18:225–35. doi: 10.1038/natimm.3647

873. Cella M, Jarrossay D, Facchetti F, Alealberi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. (1999) 5:919–23. doi: 10.1038/11360

874. Larsson M, Beignon A-S, McKenna K, Dasilva I, Amara A, Liu Y-J, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol. (2004) 78:5223–32. doi: 10.1128/JVI.78.5.5223-5232.2004

875. Haase AT, Southern PJ, Estes JD, Li Q, Lisson JD, Peterson ML, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. (2009) 458:1034–8. doi: 10.1038/nature07831

876. Izquierdo-Useros N, Lorisizate M, Puertas MC, Rodriguez-Plata MT, Zangger N, Erikson E, et al. Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol. (2012) 10:e1001448. doi: 10.1371/journal.pbio.1001448

877. Ostrowski M, Hrycza MD, Der SD, Wilkins O, Kovacs C, Lofy M, et al. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD4+ T cells. J Virol. (2007) 81:3477–86. doi: 10.1128/JVI.01552-06

878. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells from HIV-1-infected individuals. PLoS Pathog. (2010) 6:e1000781. doi: 10.1371/journal.ppat.1000781

879. Fernandez S, Tanaskovic S, Helbig K, Rajasuriar R, Kramski M, Murray JM, et al. CD4 + T-cell deficiency in HIV patients responding to interferon therapy and prophylaxis. Evol Appl. (2017) 10:297–309. doi: 10.1111/eva.12458

880. Laguette N, Sobhian B, Chable-Bessia C, Séguela E, Yatim A, Emilianii S, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. (2011) 474:965–7. doi: 10.1038/nature10117

881. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. (2002) 418:466–50. doi: 10.1038/nature00939

882. Colomer-Lluch M, Ruiz A, Moris A, Prado JG. Restriction factors: from intrinsic viral restriction to shaping cellular immunity against HIV-1. Front Immunol. (2018) 9:2876. doi: 10.3389/fimmu.2018.02876

883. Jakobsdottir GM, Lioiopoulou M, Nolan R, Alvarez L, Compton AA, Padilla-Parras S. On the whereabouts of HIV-1 cellular entry and its fusion ports. Trends Mol Med. (2017) 23:932–44. doi: 10.1016/j.molmed.2017.08.005

884. Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who’s interfering with whom? Nat Rev Microbiol. (2013) 13:403–13. doi: 10.1038/nrmicro3449

885. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. (2010) 8:55–67. doi: 10.1016/j.chom.2010.06.004

886. Lu J, Pan Q, Rong L, Liu S-L, Liang C. The IFITM Proteins Inhibit HIV-1 replication but contribute to HIV-1-induced immunopathogenesis in humanized mice. PLoS Pathog. (2010) 6:e1000781. doi: 10.1371/journal.ppat.1000781

887. Mlisana K, Kormuth E, Singh R, Ndung’u T, Werner L, Karim SSA, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted founder viruses in acute and early HIV-1 infection. J Exp Med. (2009) 206:1273–89. doi: 10.1084/jem.20090378

888. Smith DRM, Mideo N. Modelling the evolution of HIV-1 virulence in response to interferon therapy and prophylaxis. Evol Appl. (2017) 10:297–309. doi: 10.1111/eva.12458

889. Laguette N, Sobhian B, Chable-Bessia C, Séguela E, Yatim A, Emilianii S, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. (2011) 474:965–7. doi: 10.1038/nature10117

890. Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who’s interfering with whom? Nat Rev Microbiol. (2013) 13:403–13. doi: 10.1038/nrmicro3449

891. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. (2010) 8:55–67. doi: 10.1016/j.chom.2010.06.004

892. Lu J, Pan Q, Rong L, Liu S-L, Liang C. The IFITM Proteins Inhibit HIV-1 infection. J Virol. (2011) 85:2126–37. doi: 10.1128/JVI.01531-10

893. Foster TL, Wilson H, Iyer SS, Cos K, Doores K, Smith S, et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe. (2016) 20:429–42. doi: 10.1016/j.chom.2016.08.006

894. Kootstra NA, van Dort KA, Navis M, Schuitemaker H, Beugeling C. The presence of the Trim5α mutation in humanized mice. Nature. (2009) 21:2015–23. doi: 10.1097/QAD.0b013e3282effa87

895. Misiana K, Kornuth E, Singh R, Ndung’u T, Werner L, Karim SSA, et al. Human Trimm5α expression levels and reduced susceptibility to HIV-1 infection. J Infect Dis. (2009) 199:1657–63. doi: 10.1086/598861

896. van Manen D, Rits MAN, Beugeling C, Van Dort K, Schuitemaker H, Kootstra NA. The effect of Trim5α polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. (2008) 4:e18. doi: 10.1371/journal.ppat.0040018

897. Stremlau M, Owens CM, Perron MJ, Kiiessler M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature. (2004) 427:848–53. doi: 10.1038/nature2343

898. Hance AJ, Clavel F, Matsuoka S, Battivel E, Lecossier D, Mignarei J. Strain-specific differences in the impact of human TRIM5 different TRIM5 alleles, and the inhibition of capsid-cyclophilin A interactions on
the infectivity of HIV-1. J Virol. (2010) 84:11010–9. doi: 10.1128/JVI.0758-10

108. Hance AJ, Yeni P, Clavel F, Mignardes J, Battivel M, Lecossier D. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5, linking intrinsic and acquired immunity. J Virol. (2011) 85:11846–54. doi: 10.1128/JVI.05201-11

109. Arhel NJ, Kirchhoff F, Fernandez J, Machado AK, Beignon AS, Ringeard M, et al. Endogenous TRIM5α function is regulated by SUMOylation and nuclear sequestration for efficient innate sensing in dendritic cells. Cell Rep. (2015) 14:355–69. doi: 10.1016/j.celrep.2015.12.039

110. Lahouassa H, Gramberg T, Bertrand M, Logue EC, Laguette N, Pancino G, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. (2012) 13:223–8. doi: 10.1038/ni.2236

111. Polo J, Choi J, Oh C, Kim S, Seo M, Kim SY, et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat Med. (2014) 20:936–41. doi: 10.1038/nm.3626

112. Hertoghs N, van der Aar AMG, Setiawan LC, Kootstra NA, Gringhuis SI, Geijtenbeek TBH. SAMHD1 degradation enhances active suppression of dendritic cell maturation by HIV-1. J Immunol. (2015) 194:4431–7. doi: 10.4049/jimmunol.1403016

113. Posch W, Steger M, Knackmuss U, Blatzer M, Baldauf HM, Doppler W, et al. Complement-opsonized HIV-1 overcomes restriction in dendritic cells. PLoS Pathog. (2015) 11:e1005005. doi: 10.1371/journal.ppat.1005005

114. Khatua AK, Taylor HE, Hildrehn JEK, Popik W, Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. J Virol. (2008) 83:512–21. doi: 10.1128/JVI.01658-08

115. Smith LL, Smith LL, Martynow J, Swoboda W, Hunter GD, Popia G, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. (2003) 302:1056–60. doi: 10.1126/science.1089591

116. Stopak K, De Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. (2003) 12:591–601. doi: 10.1016/S1097-2765(03)00353-8

117. Perez-Caballero D, Zang T, Ebrahimia A, McNatt MW, Gregory DA, Johnson MC, et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. (2009) 139:499–511. doi: 10.1016/j.cell.2009.08.039

118. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. (2008) 451:425–30. doi: 10.1038/nature06553

119. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. (2008) 3:245–52. doi: 10.1016/j.chom.2008.03.001

120. Stephens EB, Skaske MA, Guatelli JC, Lau D, Mitchell RS, Benarous R, et al. Vpu antagonizes BST-2–mediated restriction of HIV-1 release via β-TrCP and endo-lysosomal trafficking. PLoS Pathog. (2009) 5:e1000450. doi: 10.1371/journal.ppat.1000450

121. Ota F, Hirayama T, Kiyukawa K, Yamaguchi Y, Fujinawa R, Nagata M, et al. High affinity sugar ligands of C-type lectin receptor langerin. Biochem Biophys Acta Gen Subj. (2018) 1862:1592–601. doi: 10.1016/j.bbagen.2018.04.004

122. Hegab AE, Rademacher C, Yoshida K, Hirayama T, Yamaguchi Y, Taniguchi N, et al. A keratan sulfate disaccharide prevents inflammation and the progression of emphysema in murine models. Am J Physiol Cell Mol Physiol. (2016) 312:L268–76. doi: 10.1152/ajpcell.00151.2016

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Nijmeijer and Geijtenbeek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.